101 results about "Leprosy" patented technology

The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereofwherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

The invention discloses a leprosy tree bacteria root nursery sock growing method, comprising the procedures of bacteria root agent preparation, seedling process, bacteria root agent inoculation, replanting and vaccination of seedling tubes. The invention is vaccinated with mycorrhizal fungi, which improves stress resistance and adaptability of leprosy trees. And the bacteriorhiza agent vaccination method has the advantages of little energy consumption, convenient employment, excellent production increase and extensive application scope, promotes the growing of leprosy trees and provides large numbers of high grade root bacteria seedlings for industrialized plantation of leprosy trees.

The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase activity, and a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE. Preferably, the multifunctional enzyme has substantial anti cell-cell adhesion activity. Preferably, the multifunctional enzyme has substantial homology with the krill multifunctional enzyme. These enzymes are useful for treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including autoimmune disease and cancer. Additionally, the invention relates to a method of purifying the multifunctional enzyme, and to a preparation of essentially purified multifunctional enzyme.

The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereofwherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

The invention belongs to the technical field of medicine and particularly relates to a synthetic method of the medicine for treating leprosy. The synthetic method is characterized in that phthalic anhydride and glutamic acid are used as raw materials, one-pot operation is performed, direct synthesis is performed, and then a finished product is obtained after purification. Yield is improved from 50% to about 80%. Simultaneously, N, N-dimethylformamide and other solvents are adopted in a condensation step. Compared with a solvent pyridine used in the original process, environment pollution is reduced, and cost is saved. Dimethyl sulfoxide is used as a solvent during purification, and purified mother liquor is recycled. Compared with the solvent N, N-dimethylformamide adopted by the original process, the low-toxicity solvent is used, the problem that the original process is much in impurities and unqualified in residual solvent is solved, and the purified mother liquor is recycled so as to reduce product cost further.

Disclosed are benzothiazin derivatives of formula (I), preparation methods therefore, and treatment methods employing such compounds as antibacterial agents in treating infectious diseases of mammals caused by bacteria, especially diseases like tuberculosis and leprosy caused by mycobacteria:wherein R1, R2, R3, R4, R5, and R6, and other variables enumerated under one or more of R1, R2, R3, R4, R5, and R6 are as defined.

Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.

The invention provides flatstem milkvetch seed oral liquid for improving immunity. The flatstem milkvetch seed oral liquid is prepared from the following raw materials in parts by weight: 10-50 parts of flatstem milkvetch seed, 10-20 parts of mulberry, 10-20 parts of Chinese angelica, 10-20 parts of prepared rhizome of rehmannia, 10-20 parts of astragalus membranaceus, 10-20 parts of glossy privet fruit, 10-20 parts of semen cuscutae, 10-20 parts of rhizoma polygonati, 10-20 parts of radix codonopsis, 10-20 parts of poria cocos, 10-20 parts of fructus alpiniae oxyphyllae, 10-20 parts of human placenta, 10-20 parts of dogwood, 10-20 parts of raspberry, 10-20 parts of radix paeoniae rubrathe (unpeeled) root of common peony, 10-20 parts of bighead atractylodes rhizome, 10-20 parts of dendrobium, 10-20 parts of Chinese magnoliavine fruit, and 10-20 parts of rhizoma acori graminei. The oral liquid uses the flatstem milkvetch seed as raw materials, and the traditional Chinese medicines which nourish liver and kidney, have moderate mouth feel and are easily accepted by people are added, so that the immunity can be obviously improved, and the situations that sub-health crowds are easy to have a cold, the eyes of the sub-health crowds are acerb, the sleep quality of the sub-health crowds is not high, and the sub-health crowds have splenic asthenia and weakness can be better improved; the oral liquid can alleviate the symptoms of reduced appetite, dry mouth, drinking and urine, deficiency of the kidney, soreness and weakness of waist and knees, impotence and seminal emission, tinnitus and blurring vision, premature graying hair, weak health and emaciation, leprosy and ringworm diseases; the oral liquid does not have toxicity or stimulus, so that the oral liquid is suitable for people to take for a long term.

Methods for making and using substrates of deamidase of prokaryotic ubiquitin-like protein (Dop) are described herein. More particularly, modified prokaryotic ubiquitin-like protein (Pup) and functional fragments thereof that serve as exemplary Dop substrates are described and encompassed herein. Screening methods to identify modulators of Dop and Pup activity and use of modulators identified thereby are also described. Methods of using modulators that are identified as inhibitors of Dop and Pup activity for treating diseases / conditions associated with Mycobacterium tuberculosis (Mtb) infection, such as tuberculosis and leprosy, are also envisioned.

The present invention relates to novel benzothiazin derivatives and their use as antibacterial agents in infectious diseases of mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and leprosy caused by mycobacteria.The present invention aims at the generation of new compounds with activity against mycobacteria as potential new tuberculosis drugs to overcome problems concerning resistance and drug intolerance.The solution of the present invention is a compound of the formula Iwherein R1 and R2 are, independently each from other, NO2, CN, CONR7R8, COOR9, CHO, halogen, NR7R8, SO2NR7R8, SR9, OCF3, mono-, di or trifluoromethyl;R3 and R4 are, independently each from other, H, a saturated or unsaturated, linear or branched aliphatic radical having 1-7 chain members, cycloalkyl having 3-6 carbon atoms, benzyl, SR9, OR9;R5 and R6 are, independently each from other, a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-8 chain members, cycloalkyl having 3-6 carbon atoms, phenyl, or R5 and R6 together represent a bivalent radical —(CR92)m—, or R5 and R6 together represent bivalent radicals:wherein m is 1-4, or represent bivalent radicals a saturated or unsaturated mono or polyheterocycles with heteroatoms N, S, O and substituted by (R10)x, wherein x is 1-4;R7, R8 and R9 are, independently each from other H or a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-7 chain members, mono-, di or trifluoromethyl, halogen, phenyl, or R3 and R4 together represent a bivalent radical —(CH2)n— wherein n is 2-7;R10 is H or a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-7 chain members, NO2, NR7R8, CN, CONR7R8, COOR9, CHO, halogen, SO2NR7R8, SR9, OR9, OCF3, mono-, di or trifluoromethyl, benzyl or phenyl.

The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereofwherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

The invention discloses application of single-nucleotide-polymorphism rs55882956 in screening of Hansen's disease sufferers. The technical scheme protected by the invention is as follows: application of substances for detecting polymorphism or genotype of rs55882956 in a human genome in preparation of products for screening the Hansen's disease sufferers and application of the substances for detecting the polymorphism or genotype of the rs55882956 in the human genome in the preparation of products for detecting single nucleotide polymorphism related to Hansen's disease. The substances for detecting the polymorphism or genotype of the rs55882956 and other substances (such as substances for detecting other single nucleotide polymorphisms or genotypes related to the Hansen's disease) can be combined together so as to prepare products for screening the Hansen's disease sufferers.

The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereofwherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

The invention discloses a method for directly regenerating leaf discs of Jatropha curcas. It selects annual Jatropha curcas leaves in the greenhouse as explants and inoculates them in the medium to directly induce adventitious buds; the medium is MS basic medium with 30g·L-1 sucrose, 4-8g·L-1 agar, 0.2 -2.0mg·L-1TDZ, 0.1-1.5mg·L-1IBA, 0.05-3mg·L-1BA, 0.5-8mg·L-1 Sodium Nitroprusside; culture method: first cultivate in dark for 10-14d, then switch to light Cultivate under conditions for 14-16 days; finally, the induced adventitious buds are cultured for elongation, and then transplanted after rooting culture. Adventitious bud induction rate is as high as 88%. The invention aims at providing a method for efficiently regenerating Jatropha leaf discs for gene improvement and tissue culture of Jatropha curcas. In order to realize the genetic transformation of Jatropha curcas, lay the foundation for rapid propagation, and promote the industrial development of Jatropha curcas.

The invention relates to a novel ointment for treating a microorganism infection skin disease and a preparation process thereof. The novel ointment for treating the microorganism infection skin disease consists of the following materials in part by mass: 0.1 to 0.3 part of trivalent silver ion compound, 0.2 to 0.4 part of keratinase, 0.5 to 5 parts of water-soluble keratin, 2 to 3 parts of composite vitamin and 94.3 to 98.7 parts of white petroleum jelly. The preparation process particularly comprises the following steps of: grinding 0.1 to 0.3 part of trivalent silver ion compound, 0.2 to 0.4 part of keratinase, 0.5 to 5 parts of water-soluble keratin and 2 to 3 parts of composite vitamin into powder; and adding 94.3 to 98.7 parts of white petroleum jelly into the powder and uniformly mixing the mixture. The ointment has the effects of rapidly sterilizing and relieving itching, expelling toxin and removing rot, and repairing skin. The ointment is suitable for treating and protecting a local skin disease caused by microorganism infection, such as fugal infection of hand and foot, tinea corporis, tinea cruris and onychomycosis (ringworm of the nails) caused by fungi, erysipelas and leprosy caused by bacteria, chicken pox, flat wart and herpes caused by virus and the like.